Ascent Wealth Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13M | Buy |
59,958
+1,466
| +3% | +$325K | 1.52% | 15 |
|
|
2025
Q4 | $13.4M | Sell |
58,492
-1,013
| -2% | -$231K | 1.54% | 13 |
|
|
2025
Q3 | $13.8M | Sell |
59,505
-759
| -1% | -$155K | 1.6% | 12 |
|
|
2025
Q2 | $11.2M | Sell |
60,264
-2,710
| -4% | -$504K | 1.38% | 19 |
|
|
2025
Q1 | $13.2M | Buy |
62,974
+3,132
| +5% | +$609K | 1.77% | 10 |
|
|
2024
Q4 | $10.6M | Buy |
59,842
+581
| +1% | +$107K | 1.43% | 19 |
|
|
2024
Q3 | $11.7M | Sell |
59,261
-594
| -1% | -$111K | 1.63% | 12 |
|
|
2024
Q2 | $10.3M | Sell |
59,855
-408
| -0.7% | -$67.6K | 1.5% | 16 |
|
|
2024
Q1 | $11M | Buy |
60,263
+134
| +0.2% | +$23.1K | 1.63% | 12 |
|
|
2023
Q4 | $9.32M | Buy |
60,129
+696
| +1% | +$101K | 1.52% | 13 |
|
|
2023
Q3 | $8.86M | Sell |
59,433
-634
| -1% | -$93.1K | 1.63% | 13 |
|
|
2023
Q2 | $7.98M | Buy |
60,067
+5,597
| +10% | +$821K | 1.41% | 18 |
|
|
2023
Q1 | $8.59M | Buy |
54,470
+809
| +2% | +$124K | 1.73% | 12 |
|
|
2022
Q4 | $8.67M | Sell |
53,661
-946
| -2% | -$145K | 1.86% | 13 |
|
|
2022
Q3 | $7.33M | Sell |
54,607
-3,601
| -6% | -$517K | 1.75% | 16 |
|
|
2022
Q2 | $8.91M | Sell |
58,208
-1,207
| -2% | -$184K | 2% | 12 |
|
|
2022
Q1 | $9.63M | Buy |
59,415
+2,499
| +4% | +$363K | 1.8% | 10 |
|
|
2021
Q4 | $7.71M | Sell |
56,916
-2,606
| -4% | -$308K | 1.37% | 18 |
|
|
2021
Q3 | $6.42M | Sell |
59,522
-909
| -2% | -$104K | 1.23% | 21 |
|
|
2021
Q2 | $6.81M | Buy |
60,431
+244
| +0.4% | +$27.5K | 1.3% | 19 |
|
|
2021
Q1 | $6.51M | Buy |
60,187
+1,204
| +2% | +$129K | 1.41% | 18 |
|
|
2020
Q4 | $6.32M | Buy |
58,983
+228
| +0.4% | +$21.9K | 1.41% | 19 |
|
|
2020
Q3 | $5.15M | Buy |
58,755
+1,114
| +2% | +$105K | 1.32% | 25 |
|
|
2020
Q2 | $5.66M | Buy |
57,641
+1,204
| +2% | +$106K | 1.64% | 16 |
|
|
2020
Q1 | $4.3M | Buy |
56,437
+403
| +0.7% | +$34.3K | 1.57% | 22 |
|
|
2019
Q4 | $4.96M | Sell |
56,034
-91
| -0.2% | -$7.55K | 1.41% | 22 |
|
|
2019
Q3 | $4.25M | Buy |
56,125
+492
| +0.9% | +$33.7K | 1.3% | 26 |
|
|
2019
Q2 | $4.04M | Buy |
55,633
+870
| +2% | +$68.4K | 1.25% | 28 |
|
|
2019
Q1 | $4.41M | Buy |
54,763
+3,298
| +6% | +$270K | 1.44% | 20 |
|
|
2018
Q4 | $4.75M | Buy |
51,465
+1
| +0% | +$88 | 1.85% | 15 |
|
|
2018
Q3 | $4.87M | Buy |
51,464
+1,188
| +2% | +$113K | 1.55% | 18 |
|
|
2018
Q2 | $4.66M | Buy |
50,276
+1,169
| +2% | +$114K | 1.64% | 18 |
|
|
2018
Q1 | $4.65M | Sell |
49,107
-84
| -0.2% | -$9.23K | 1.69% | 17 |
|
|
2017
Q4 | $4.76M | Buy |
49,191
+379
| +0.8% | +$35.7K | 1.77% | 16 |
|
|
2017
Q3 | $4.34M | Sell |
48,812
-140
| -0.3% | -$10.7K | 1.74% | 16 |
|
|
2017
Q2 | $3.55M | Sell |
48,952
-450
| -0.9% | -$30.3K | 1.53% | 21 |
|
|
2017
Q1 | $3.22M | Buy |
49,402
+460
| +0.9% | +$28.9K | 1.45% | 24 |
|
|
2016
Q4 | $3.06M | Buy |
48,942
+69
| +0.1% | +$4.21K | 1.5% | 23 |
|
|
2016
Q3 | $3.08M | Sell |
48,873
-138
| -0.3% | -$8.93K | 1.56% | 19 |
|
|
2016
Q2 | $3.03M | Buy |
49,011
+260
| +0.5% | +$15.8K | 1.57% | 22 |
|
|
2016
Q1 | $2.79M | Buy |
48,751
+515
| +1% | +$28.7K | 1.5% | 22 |
|
|
2015
Q4 | $2.85M | Buy |
48,236
+710
| +1% | +$40.9K | 1.59% | 22 |
|
|
2015
Q3 | $2.59M | Buy |
47,526
+360
| +0.8% | +$23.4K | 1.54% | 21 |
|
|
2015
Q2 | $3.17M | Buy |
47,166
+525
| +1% | +$34.3K | 1.74% | 18 |
|
|
2015
Q1 | $2.73M | Buy |
46,641
+15,590
| +50% | +$942K | 1.49% | 28 |
|
|
2014
Q4 | $2.03M | Buy |
31,051
+804
| +3% | +$50.7K | 1.19% | 39 |
|
|
2014
Q3 | $1.75M | Buy |
30,247
+65
| +0.2% | +$3.61K | 1.11% | 42 |
|
|
2014
Q2 | $1.7M | Buy |
30,182
+615
| +2% | +$32.3K | 1.08% | 45 |
|
|
2014
Q1 | $1.52M | Buy |
29,567
+445
| +2% | +$22.5K | 1.04% | 46 |
|
|
2013
Q4 | $1.54M | Buy |
+29,122
| New | +$1.43M | 1.09% | 47 |
|
Other funds holding ABBV
VCM
VPM
Ascent Wealth Partners's ABBV Position: Q1 2026 in Review
Ascent Wealth Partners increased its AbbVie (ABBV) stake by 2.5% in Q1 2026, buying an estimated $325K and bringing the position to 59,958 shares worth $13M. The position accounts for 1.52% of the portfolio, ranked #15.
Ascent Wealth Partners first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $13.8M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Ascent Wealth Partners held 59,958 shares of AbbVie worth $13M as of Q1 2026.
- Ascent Wealth Partners bought 1,466 AbbVie shares in Q1 2026, an estimated $325K.
- AbbVie made up 1.52% of Ascent Wealth Partners's portfolio in Q1 2026, its #15 holding.
- Ascent Wealth Partners first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
- Ascent Wealth Partners's AbbVie position peaked at $13.8M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Ascent Wealth Partners's 13F filing for Q1 2026, filed 6 May 2026.